Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease
Background Biomarker for usefulness in diagnosing advanced fibrosis in nonalcoholic fatty liver disease (NAFLD) is expected. In order to discover novel biomarkers for NAFLD and its pathogenesis, we performed matabolomics screening. Methods (1) The initial cohort was 44 NAFLD patients. (2) This valid...
Gespeichert in:
| Veröffentlicht in: | Journal of gastroenterology 2013-12, Vol.48 (12), p.1392-1400 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1400 |
|---|---|
| container_issue | 12 |
| container_start_page | 1392 |
| container_title | Journal of gastroenterology |
| container_volume | 48 |
| creator | Tokushige, Katsutoshi Hashimoto, Etsuko Kodama, Kazuhisa Tobari, Maki Matsushita, Noriko Kogiso, Tomomi Taniai, Makiko Torii, Nobuyuki Shiratori, Keiko Nishizaki, Yasuhiro Ohga, Takushi Ohashi, Yoshiaki Sato, Takaya |
| description | Background
Biomarker for usefulness in diagnosing advanced fibrosis in nonalcoholic fatty liver disease (NAFLD) is expected. In order to discover novel biomarkers for NAFLD and its pathogenesis, we performed matabolomics screening.
Methods
(1) The initial cohort was 44 NAFLD patients. (2) This validation cohort was 105 NAFLD patients, 26 primary biliary cirrhosis (PBC) patients, and 48 healthy controls. Using capillary electrophoresis and liquid chromatography with mass spectrometry, we analyzed low molecular weight metabolites in these groups.
Results
1. In the initial cohort, we found 28 metabolites associated with advanced fibrosis. Among them, 4 sulfated steroids showed the greatest difference. A decrease of dehydroepiandrosterone sulfate (DHEA-S) and 5α-androstan-3β ol-17-one sulfate (etiocholanolone-S) was observed with the progression of fibrosis. Furthermore, 16 hydroxydehydroepiandrosterone sulfate (16-OH-DHEA-S) increased with the progression of fibrosis. 2. In the validation cohort, the decrease of DHEA-S and etiocholanolone-S, as well as the increase of 16-OH-DHEA-S, with the progression of fibrosis was confirmed. The 16-OH-DHEA-S/DHEA-S ratio and 16-OH-DHEA-S/etiocholanolone-S ratio were even more strongly associated with the grade of fibrosis. Among PBC patients, 16-OH-DHEA-S tended to be higher in stages 3 and 4 than in stages 1 and 2. However, levels of DHEA-S, etiocholanolone-S, and the two ratios were not associated with the stage of PBC.
Conclusion
Several metabolic products were found to be biomarkers of fibrosis in NAFLD and could also be useful for diagnosis of this condition. Our findings suggested disturbance of hormone metabolism in NAFLD and might lead to the development of new therapy. |
| doi_str_mv | 10.1007/s00535-013-0766-5 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3889284</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A714584175</galeid><sourcerecordid>A714584175</sourcerecordid><originalsourceid>FETCH-LOGICAL-c627t-ebacb68fb32fc0ba28b22b454a1809868bf90f39efd51c0dc609ea0e3c2d302c3</originalsourceid><addsrcrecordid>eNp1kk1rFTEUhoMo9lr9AW4k4MbN1HzNTLIRSvELCi7UdUgyJ7epmeSazC303zfjrbUVJYtAzvO-4ZzzIvSSkhNKyPi2EtLzviOUd2Qchq5_hDZUtJdeMfYYbYgSoqN0FEfoWa2XpIGkl0_REeNilIoPG5S_QtnPeIbF2BzzHBzelexDBGzShHd5gbQEE7ENeTblB5SKfS64whWUsFzj7LEPtuQaKg4Jp5xMdPkix-bkzdKIGBqKp1DBVHiOnngTK7y4vY_R9w_vv5196s6_fPx8dnreuYGNSwfWODtIbznzjljDpGXMil4YKomSg7ReEc8V-KmnjkxuIAoMAe7YxAlz_Bi9O_ju9naGybUuiol6V0Lr4lpnE_TDSgoXepuvNJdSMSmawZtbg5J_7qEueg7VQYwmQd5XTcWgBqEElw19_Rd6mfelzeEXJSUllPZ_qK2JoEPyuf3rVlN9OlLRS0HHlTr5B9XOBG03OcG6mocCehC4toNawN_1SIleU6IPKdFt-XpNiV41r-4P507xOxYNYAegtlLaQrnX0X9dbwDXxsmg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1468810115</pqid></control><display><type>article</type><title>Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Tokushige, Katsutoshi ; Hashimoto, Etsuko ; Kodama, Kazuhisa ; Tobari, Maki ; Matsushita, Noriko ; Kogiso, Tomomi ; Taniai, Makiko ; Torii, Nobuyuki ; Shiratori, Keiko ; Nishizaki, Yasuhiro ; Ohga, Takushi ; Ohashi, Yoshiaki ; Sato, Takaya</creator><creatorcontrib>Tokushige, Katsutoshi ; Hashimoto, Etsuko ; Kodama, Kazuhisa ; Tobari, Maki ; Matsushita, Noriko ; Kogiso, Tomomi ; Taniai, Makiko ; Torii, Nobuyuki ; Shiratori, Keiko ; Nishizaki, Yasuhiro ; Ohga, Takushi ; Ohashi, Yoshiaki ; Sato, Takaya</creatorcontrib><description>Background
Biomarker for usefulness in diagnosing advanced fibrosis in nonalcoholic fatty liver disease (NAFLD) is expected. In order to discover novel biomarkers for NAFLD and its pathogenesis, we performed matabolomics screening.
Methods
(1) The initial cohort was 44 NAFLD patients. (2) This validation cohort was 105 NAFLD patients, 26 primary biliary cirrhosis (PBC) patients, and 48 healthy controls. Using capillary electrophoresis and liquid chromatography with mass spectrometry, we analyzed low molecular weight metabolites in these groups.
Results
1. In the initial cohort, we found 28 metabolites associated with advanced fibrosis. Among them, 4 sulfated steroids showed the greatest difference. A decrease of dehydroepiandrosterone sulfate (DHEA-S) and 5α-androstan-3β ol-17-one sulfate (etiocholanolone-S) was observed with the progression of fibrosis. Furthermore, 16 hydroxydehydroepiandrosterone sulfate (16-OH-DHEA-S) increased with the progression of fibrosis. 2. In the validation cohort, the decrease of DHEA-S and etiocholanolone-S, as well as the increase of 16-OH-DHEA-S, with the progression of fibrosis was confirmed. The 16-OH-DHEA-S/DHEA-S ratio and 16-OH-DHEA-S/etiocholanolone-S ratio were even more strongly associated with the grade of fibrosis. Among PBC patients, 16-OH-DHEA-S tended to be higher in stages 3 and 4 than in stages 1 and 2. However, levels of DHEA-S, etiocholanolone-S, and the two ratios were not associated with the stage of PBC.
Conclusion
Several metabolic products were found to be biomarkers of fibrosis in NAFLD and could also be useful for diagnosis of this condition. Our findings suggested disturbance of hormone metabolism in NAFLD and might lead to the development of new therapy.</description><identifier>ISSN: 0944-1174</identifier><identifier>EISSN: 1435-5922</identifier><identifier>DOI: 10.1007/s00535-013-0766-5</identifier><identifier>PMID: 23478936</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Abdominal Surgery ; Adult ; Aged ; Aged, 80 and over ; Biliary Tract ; Biological markers ; Biomarkers - metabolism ; Case-Control Studies ; Chromatography, Liquid - methods ; Cohort Studies ; Colorectal Surgery ; Dehydroepiandrosterone ; Disease Progression ; Electrophoresis, Capillary - methods ; Fatty liver ; Fatty Liver - diagnosis ; Fatty Liver - metabolism ; Fatty Liver - physiopathology ; Female ; Fibrosis ; Gastroenterology ; Hepatology ; Hormones, Sex ; Humans ; Liquid chromatography ; Liver cirrhosis ; Liver Cirrhosis - diagnosis ; Liver Cirrhosis - metabolism ; Liver Cirrhosis - physiopathology ; Liver Cirrhosis, Biliary - diagnosis ; Liver Cirrhosis, Biliary - metabolism ; Liver Cirrhosis, Biliary - physiopathology ; Male ; Mass spectrometry ; Mass Spectrometry - methods ; Medicine ; Medicine & Public Health ; Metabolites ; Metabolomics - methods ; Middle Aged ; Non-alcoholic Fatty Liver Disease ; Original Article—Liver ; Original —Liver, Pancreas, and Biliary Tract ; Pancreas ; Severity of Illness Index ; Sulfates ; Surgical Oncology ; Type 2 diabetes</subject><ispartof>Journal of gastroenterology, 2013-12, Vol.48 (12), p.1392-1400</ispartof><rights>The Author(s) 2013</rights><rights>COPYRIGHT 2013 Springer</rights><rights>Springer Japan 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c627t-ebacb68fb32fc0ba28b22b454a1809868bf90f39efd51c0dc609ea0e3c2d302c3</citedby><cites>FETCH-LOGICAL-c627t-ebacb68fb32fc0ba28b22b454a1809868bf90f39efd51c0dc609ea0e3c2d302c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00535-013-0766-5$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00535-013-0766-5$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,315,781,785,886,27928,27929,41492,42561,51323</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23478936$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tokushige, Katsutoshi</creatorcontrib><creatorcontrib>Hashimoto, Etsuko</creatorcontrib><creatorcontrib>Kodama, Kazuhisa</creatorcontrib><creatorcontrib>Tobari, Maki</creatorcontrib><creatorcontrib>Matsushita, Noriko</creatorcontrib><creatorcontrib>Kogiso, Tomomi</creatorcontrib><creatorcontrib>Taniai, Makiko</creatorcontrib><creatorcontrib>Torii, Nobuyuki</creatorcontrib><creatorcontrib>Shiratori, Keiko</creatorcontrib><creatorcontrib>Nishizaki, Yasuhiro</creatorcontrib><creatorcontrib>Ohga, Takushi</creatorcontrib><creatorcontrib>Ohashi, Yoshiaki</creatorcontrib><creatorcontrib>Sato, Takaya</creatorcontrib><title>Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease</title><title>Journal of gastroenterology</title><addtitle>J Gastroenterol</addtitle><addtitle>J Gastroenterol</addtitle><description>Background
Biomarker for usefulness in diagnosing advanced fibrosis in nonalcoholic fatty liver disease (NAFLD) is expected. In order to discover novel biomarkers for NAFLD and its pathogenesis, we performed matabolomics screening.
Methods
(1) The initial cohort was 44 NAFLD patients. (2) This validation cohort was 105 NAFLD patients, 26 primary biliary cirrhosis (PBC) patients, and 48 healthy controls. Using capillary electrophoresis and liquid chromatography with mass spectrometry, we analyzed low molecular weight metabolites in these groups.
Results
1. In the initial cohort, we found 28 metabolites associated with advanced fibrosis. Among them, 4 sulfated steroids showed the greatest difference. A decrease of dehydroepiandrosterone sulfate (DHEA-S) and 5α-androstan-3β ol-17-one sulfate (etiocholanolone-S) was observed with the progression of fibrosis. Furthermore, 16 hydroxydehydroepiandrosterone sulfate (16-OH-DHEA-S) increased with the progression of fibrosis. 2. In the validation cohort, the decrease of DHEA-S and etiocholanolone-S, as well as the increase of 16-OH-DHEA-S, with the progression of fibrosis was confirmed. The 16-OH-DHEA-S/DHEA-S ratio and 16-OH-DHEA-S/etiocholanolone-S ratio were even more strongly associated with the grade of fibrosis. Among PBC patients, 16-OH-DHEA-S tended to be higher in stages 3 and 4 than in stages 1 and 2. However, levels of DHEA-S, etiocholanolone-S, and the two ratios were not associated with the stage of PBC.
Conclusion
Several metabolic products were found to be biomarkers of fibrosis in NAFLD and could also be useful for diagnosis of this condition. Our findings suggested disturbance of hormone metabolism in NAFLD and might lead to the development of new therapy.</description><subject>Abdominal Surgery</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biliary Tract</subject><subject>Biological markers</subject><subject>Biomarkers - metabolism</subject><subject>Case-Control Studies</subject><subject>Chromatography, Liquid - methods</subject><subject>Cohort Studies</subject><subject>Colorectal Surgery</subject><subject>Dehydroepiandrosterone</subject><subject>Disease Progression</subject><subject>Electrophoresis, Capillary - methods</subject><subject>Fatty liver</subject><subject>Fatty Liver - diagnosis</subject><subject>Fatty Liver - metabolism</subject><subject>Fatty Liver - physiopathology</subject><subject>Female</subject><subject>Fibrosis</subject><subject>Gastroenterology</subject><subject>Hepatology</subject><subject>Hormones, Sex</subject><subject>Humans</subject><subject>Liquid chromatography</subject><subject>Liver cirrhosis</subject><subject>Liver Cirrhosis - diagnosis</subject><subject>Liver Cirrhosis - metabolism</subject><subject>Liver Cirrhosis - physiopathology</subject><subject>Liver Cirrhosis, Biliary - diagnosis</subject><subject>Liver Cirrhosis, Biliary - metabolism</subject><subject>Liver Cirrhosis, Biliary - physiopathology</subject><subject>Male</subject><subject>Mass spectrometry</subject><subject>Mass Spectrometry - methods</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolites</subject><subject>Metabolomics - methods</subject><subject>Middle Aged</subject><subject>Non-alcoholic Fatty Liver Disease</subject><subject>Original Article—Liver</subject><subject>Original —Liver, Pancreas, and Biliary Tract</subject><subject>Pancreas</subject><subject>Severity of Illness Index</subject><subject>Sulfates</subject><subject>Surgical Oncology</subject><subject>Type 2 diabetes</subject><issn>0944-1174</issn><issn>1435-5922</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kk1rFTEUhoMo9lr9AW4k4MbN1HzNTLIRSvELCi7UdUgyJ7epmeSazC303zfjrbUVJYtAzvO-4ZzzIvSSkhNKyPi2EtLzviOUd2Qchq5_hDZUtJdeMfYYbYgSoqN0FEfoWa2XpIGkl0_REeNilIoPG5S_QtnPeIbF2BzzHBzelexDBGzShHd5gbQEE7ENeTblB5SKfS64whWUsFzj7LEPtuQaKg4Jp5xMdPkix-bkzdKIGBqKp1DBVHiOnngTK7y4vY_R9w_vv5196s6_fPx8dnreuYGNSwfWODtIbznzjljDpGXMil4YKomSg7ReEc8V-KmnjkxuIAoMAe7YxAlz_Bi9O_ju9naGybUuiol6V0Lr4lpnE_TDSgoXepuvNJdSMSmawZtbg5J_7qEueg7VQYwmQd5XTcWgBqEElw19_Rd6mfelzeEXJSUllPZ_qK2JoEPyuf3rVlN9OlLRS0HHlTr5B9XOBG03OcG6mocCehC4toNawN_1SIleU6IPKdFt-XpNiV41r-4P507xOxYNYAegtlLaQrnX0X9dbwDXxsmg</recordid><startdate>20131201</startdate><enddate>20131201</enddate><creator>Tokushige, Katsutoshi</creator><creator>Hashimoto, Etsuko</creator><creator>Kodama, Kazuhisa</creator><creator>Tobari, Maki</creator><creator>Matsushita, Noriko</creator><creator>Kogiso, Tomomi</creator><creator>Taniai, Makiko</creator><creator>Torii, Nobuyuki</creator><creator>Shiratori, Keiko</creator><creator>Nishizaki, Yasuhiro</creator><creator>Ohga, Takushi</creator><creator>Ohashi, Yoshiaki</creator><creator>Sato, Takaya</creator><general>Springer Japan</general><general>Springer</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20131201</creationdate><title>Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease</title><author>Tokushige, Katsutoshi ; Hashimoto, Etsuko ; Kodama, Kazuhisa ; Tobari, Maki ; Matsushita, Noriko ; Kogiso, Tomomi ; Taniai, Makiko ; Torii, Nobuyuki ; Shiratori, Keiko ; Nishizaki, Yasuhiro ; Ohga, Takushi ; Ohashi, Yoshiaki ; Sato, Takaya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c627t-ebacb68fb32fc0ba28b22b454a1809868bf90f39efd51c0dc609ea0e3c2d302c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Abdominal Surgery</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biliary Tract</topic><topic>Biological markers</topic><topic>Biomarkers - metabolism</topic><topic>Case-Control Studies</topic><topic>Chromatography, Liquid - methods</topic><topic>Cohort Studies</topic><topic>Colorectal Surgery</topic><topic>Dehydroepiandrosterone</topic><topic>Disease Progression</topic><topic>Electrophoresis, Capillary - methods</topic><topic>Fatty liver</topic><topic>Fatty Liver - diagnosis</topic><topic>Fatty Liver - metabolism</topic><topic>Fatty Liver - physiopathology</topic><topic>Female</topic><topic>Fibrosis</topic><topic>Gastroenterology</topic><topic>Hepatology</topic><topic>Hormones, Sex</topic><topic>Humans</topic><topic>Liquid chromatography</topic><topic>Liver cirrhosis</topic><topic>Liver Cirrhosis - diagnosis</topic><topic>Liver Cirrhosis - metabolism</topic><topic>Liver Cirrhosis - physiopathology</topic><topic>Liver Cirrhosis, Biliary - diagnosis</topic><topic>Liver Cirrhosis, Biliary - metabolism</topic><topic>Liver Cirrhosis, Biliary - physiopathology</topic><topic>Male</topic><topic>Mass spectrometry</topic><topic>Mass Spectrometry - methods</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolites</topic><topic>Metabolomics - methods</topic><topic>Middle Aged</topic><topic>Non-alcoholic Fatty Liver Disease</topic><topic>Original Article—Liver</topic><topic>Original —Liver, Pancreas, and Biliary Tract</topic><topic>Pancreas</topic><topic>Severity of Illness Index</topic><topic>Sulfates</topic><topic>Surgical Oncology</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tokushige, Katsutoshi</creatorcontrib><creatorcontrib>Hashimoto, Etsuko</creatorcontrib><creatorcontrib>Kodama, Kazuhisa</creatorcontrib><creatorcontrib>Tobari, Maki</creatorcontrib><creatorcontrib>Matsushita, Noriko</creatorcontrib><creatorcontrib>Kogiso, Tomomi</creatorcontrib><creatorcontrib>Taniai, Makiko</creatorcontrib><creatorcontrib>Torii, Nobuyuki</creatorcontrib><creatorcontrib>Shiratori, Keiko</creatorcontrib><creatorcontrib>Nishizaki, Yasuhiro</creatorcontrib><creatorcontrib>Ohga, Takushi</creatorcontrib><creatorcontrib>Ohashi, Yoshiaki</creatorcontrib><creatorcontrib>Sato, Takaya</creatorcontrib><collection>Springer Nature OA/Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tokushige, Katsutoshi</au><au>Hashimoto, Etsuko</au><au>Kodama, Kazuhisa</au><au>Tobari, Maki</au><au>Matsushita, Noriko</au><au>Kogiso, Tomomi</au><au>Taniai, Makiko</au><au>Torii, Nobuyuki</au><au>Shiratori, Keiko</au><au>Nishizaki, Yasuhiro</au><au>Ohga, Takushi</au><au>Ohashi, Yoshiaki</au><au>Sato, Takaya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease</atitle><jtitle>Journal of gastroenterology</jtitle><stitle>J Gastroenterol</stitle><addtitle>J Gastroenterol</addtitle><date>2013-12-01</date><risdate>2013</risdate><volume>48</volume><issue>12</issue><spage>1392</spage><epage>1400</epage><pages>1392-1400</pages><issn>0944-1174</issn><eissn>1435-5922</eissn><abstract>Background
Biomarker for usefulness in diagnosing advanced fibrosis in nonalcoholic fatty liver disease (NAFLD) is expected. In order to discover novel biomarkers for NAFLD and its pathogenesis, we performed matabolomics screening.
Methods
(1) The initial cohort was 44 NAFLD patients. (2) This validation cohort was 105 NAFLD patients, 26 primary biliary cirrhosis (PBC) patients, and 48 healthy controls. Using capillary electrophoresis and liquid chromatography with mass spectrometry, we analyzed low molecular weight metabolites in these groups.
Results
1. In the initial cohort, we found 28 metabolites associated with advanced fibrosis. Among them, 4 sulfated steroids showed the greatest difference. A decrease of dehydroepiandrosterone sulfate (DHEA-S) and 5α-androstan-3β ol-17-one sulfate (etiocholanolone-S) was observed with the progression of fibrosis. Furthermore, 16 hydroxydehydroepiandrosterone sulfate (16-OH-DHEA-S) increased with the progression of fibrosis. 2. In the validation cohort, the decrease of DHEA-S and etiocholanolone-S, as well as the increase of 16-OH-DHEA-S, with the progression of fibrosis was confirmed. The 16-OH-DHEA-S/DHEA-S ratio and 16-OH-DHEA-S/etiocholanolone-S ratio were even more strongly associated with the grade of fibrosis. Among PBC patients, 16-OH-DHEA-S tended to be higher in stages 3 and 4 than in stages 1 and 2. However, levels of DHEA-S, etiocholanolone-S, and the two ratios were not associated with the stage of PBC.
Conclusion
Several metabolic products were found to be biomarkers of fibrosis in NAFLD and could also be useful for diagnosis of this condition. Our findings suggested disturbance of hormone metabolism in NAFLD and might lead to the development of new therapy.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>23478936</pmid><doi>10.1007/s00535-013-0766-5</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0944-1174 |
| ispartof | Journal of gastroenterology, 2013-12, Vol.48 (12), p.1392-1400 |
| issn | 0944-1174 1435-5922 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3889284 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Abdominal Surgery Adult Aged Aged, 80 and over Biliary Tract Biological markers Biomarkers - metabolism Case-Control Studies Chromatography, Liquid - methods Cohort Studies Colorectal Surgery Dehydroepiandrosterone Disease Progression Electrophoresis, Capillary - methods Fatty liver Fatty Liver - diagnosis Fatty Liver - metabolism Fatty Liver - physiopathology Female Fibrosis Gastroenterology Hepatology Hormones, Sex Humans Liquid chromatography Liver cirrhosis Liver Cirrhosis - diagnosis Liver Cirrhosis - metabolism Liver Cirrhosis - physiopathology Liver Cirrhosis, Biliary - diagnosis Liver Cirrhosis, Biliary - metabolism Liver Cirrhosis, Biliary - physiopathology Male Mass spectrometry Mass Spectrometry - methods Medicine Medicine & Public Health Metabolites Metabolomics - methods Middle Aged Non-alcoholic Fatty Liver Disease Original Article—Liver Original —Liver, Pancreas, and Biliary Tract Pancreas Severity of Illness Index Sulfates Surgical Oncology Type 2 diabetes |
| title | Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T19%3A18%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20metabolomic%20profile%20and%20potential%20biomarkers%20for%20severity%20of%20fibrosis%20in%20nonalcoholic%20fatty%20liver%20disease&rft.jtitle=Journal%20of%20gastroenterology&rft.au=Tokushige,%20Katsutoshi&rft.date=2013-12-01&rft.volume=48&rft.issue=12&rft.spage=1392&rft.epage=1400&rft.pages=1392-1400&rft.issn=0944-1174&rft.eissn=1435-5922&rft_id=info:doi/10.1007/s00535-013-0766-5&rft_dat=%3Cgale_pubme%3EA714584175%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1468810115&rft_id=info:pmid/23478936&rft_galeid=A714584175&rfr_iscdi=true |